Executive leadership at MEDICINOVA.
Board of directors at MEDICINOVA.
Research analysts covering MEDICINOVA.
Recent press releases and 8-K filings for MNOV.
MediciNova Provides Corporate Update and Clinical Development Milestones
MNOV
New Projects/Investments
Guidance Update
- MediciNova completed patient enrollment in three key clinical trials in late 2025: the COMBAT-ALS Study (Phase 2b/3 for ALS) in September 2025, the OXTOX Study (Phase 2b for chemotherapy-induced peripheral neuropathy) in December 2025, and the MN-001-NATG-202 Study (Phase 2 for hypertriglyceridemia, NAFLD, and T2DM) in November 2025.
- Top-line results for the COMBAT-ALS Study are expected by year-end 2026, and for the MN-001-NATG-202 Study in summer 2026.
- The company initiated an Expanded Access Program for ALS in March 2025, supported by a $22 million NIH research grant, with 87 patients enrolled across 12 U.S. sites as of December 15, 2025.
- CEO Yuichi Iwaki stated that 2026 will be a pivotal year for MediciNova, aiming to reach long-term goals.
Jan 6, 2026, 2:00 PM
MediciNova Enters into Equity Distribution Agreement
MNOV
- MediciNova, Inc. entered into an Equity Distribution Agreement with Lucid Capital Markets, LLC on December 29, 2025.
- Under this agreement, MediciNova may sell shares of its common stock with a maximum aggregate offering price of $50,000,000 through an "at the market offering".
- Lucid Capital Markets, LLC will act as the sales agent and receive 3.0% of the gross sales price for all shares sold.
- MediciNova has also agreed to reimburse the Agent for certain legal expenses, up to $75,000.
Dec 30, 2025, 12:53 PM
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
MNOV
New Projects/Investments
- MediciNova, Inc. has successfully achieved enrollment of the target number of participants in its COMBAT-ALS Phase 2b/3 clinical trial.
- The trial is evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS).
- This milestone is considered a significant step forward in the development of MN-166, allowing the company to move into the next phase of the trial.
- MN-166 is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, and is also in development for other neurodegenerative diseases such as progressive MS and DCM.
Aug 26, 2025, 11:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more